Clinical trials: Severe Nonproliferative Diabetic Retinopathy
Diabetic Macular Edema
Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy
The goal of this prospective multicenter open label study is to evaluate the efficacy and safety of intravitreal injection Conbercept (IVC) for the treatment of diabetic macular edema (DME) combined with severe nonproliferative…
- Trial name
- NCT06305143
- Testing
- Conbercept
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Diabetic Retinopathy
Evaluation of RC28-E Injection in Diabetic Retinopathy
This is a randomized, open-label, multicenter study of the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in the treatment of patients with moderately…
- Trial name
- NCT04782128
- Testing
- RC28-E injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Non Proliferative Diabetic Retinopathy(NPDR)
Clinical Study on Prognosis of Patients With Severe NPDR Undergoing Vitrectomy
To investigate the prognosis of retinal structure and function after vitrectomy in patients with severe non-proliferative diabetic retinopathy, to explore the feasibility of vitrectomy in patients with severe non-proliferative…
- Trial name
- NCT05852132
- Testing
- pars plana vitrectomy(PPV), Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP), Panretinal photocoagulation(PRP)
- Where
- China
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Fei Gao
Non Proliferative Diabetic Retinopathy
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR
It is estimated that there are about 600 million diabetes mellitus (DM) patients all over the world until 2040，and almost 50% of whom have some degree of diabetic retinopathy (DR) at any given time.
- Trial name
- NCT04103671
- Testing
- Prompt panretinal photocoagulation, 25G Pars-plana vitrectomy
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography…
- Trial name
- NEON-NPDR (NCT04722991)
- Testing
- Runcaciguat (BAY1101042)
- Where
- 55 sites in United States, Bulgaria and 12 more
- Volunteers
- 109 people
- Sponsor
- Bayer
Nonproliferative Diabetic Retinopathy
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy…
- Trial name
- TIME-2b (NCT03197870)
- Testing
- AKB-9778
- Where
- 53 sites in United States
- Volunteers
- 167 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Severe Nonproliferative, Proliferative Diabetic Retinopathy
Intravitreal Bevacizumab for Diabetic Retinopathy
Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on the progression of severe non proliferative diabetic retinopathy, proliferative diabetic retinopathy and active photocoagulated diabetic…
- Conditions
- Severe Nonproliferative, Proliferative Diabetic Retinopathy, Active Photocoagulated Diabetic Retinopathy
- Trial name
- NCT00600262
- Testing
- intravitreal bevacizumab
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Severe Non-proliferative Diabetic Retinopathy
Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR
This randomized, parallel controlled, clinical-trial aims to evaluate the therapeutic efficacy of 532nm laser partially subthreshold panretinal photocoagulation with PASCAL endpoint management function for severe…
- Trial name
- S-PRP (NCT01759121)
- Testing
- T-PRP, S-PRP
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy
Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography
The purpose of this study is explore if a partnership and screening program put in place between a busy retina practice and their referring diabetes care offices can improve diabetic retinopathy and diabetic macular edema…
- Conditions
- Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy, Severe Nonproliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Trial name
- DIVER (NCT01790945)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Retina Institute of Hawaii
Diabetic Retinopathy
Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy
This 24 month randomized research study will evaluate whether doxycycline can 1) slow the deterioration or improve retinal function and/or 2) induce regression, or slow progression, of diabetic retinopathy in participants over 18…
- Trial name
- POC1 (NCT00511875)
- Testing
- doxycycline monohydrate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Gardner
Non-proliferative Diabetic Retinopathy
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05695417
- Testing
- OTX-TKI
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ocular Therapeutix, Inc.
Non-proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
- Trial name
- GLOW (NCT05066230)
- Testing
- KSI-301
- Where
- 61 sites in United States, Czechia and 5 more
- Volunteers
- 253 people
- Sponsor
- Kodiak Sciences Inc
Vitreous Detachment, Diabetic Retinopathy
Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment
The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.
- Trial name
- NCT00198471
- Testing
- Vitrase
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bausch & Lomb Incorporated
Diabetic Retinopathy
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248131
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 260 people
- Sponsor
- Novartis Pharmaceuticals
Non-proliferative Diabetic Retinopathy
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
In this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will be included and divided randomly into 2 groups: Intravitreal Bevacizumab group (50 eyes) that receive 6 bimonthly intravitreal…
- Trial name
- NCT04511715
- Testing
- Intravitreal Bevacizumab IVB, Follow-up with regular examination for determination of DR progression
- Volunteers
- 100 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Nonproliferative Diabetic Retinopathy
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).
- Trial name
- PANORAMA (NCT02718326)
- Testing
- Intravitreal aflibercept injection [IAI]
- Where
- 89 sites in United States, Germany and 4 more
- Volunteers
- 402 people
- Sponsor
- Regeneron Pharmaceuticals
Severe Non-proliferative Diabetic Retinopathy
Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy
Diabetic retinopathy (DR) is a leading cause of new cases of blindness in people aged 20 to 65 years worldwide. Patients with DR may go on to develop a more severe form of the disease called Proliferative Diabetic Retinopathy…
- Trial name
- PRPhS (NCT02309502)
- Testing
- Green Pascal, Yellow Pascal
- Where
- United Kingdom
- Sponsor
- Manchester University NHS Foundation Trust
Diabetic Retinopathy
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina).
- Trial name
- NAAVIGATE (NCT07592273)
- Testing
- Surabgene Lomparvovec, Topical Steroid, Artificial Tears
- Where
- 40 sites in United States, Puerto Rico
- Volunteers
- 576 people
- Sponsor
- AbbVie
Diabetic Retinopathy
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.
- Trial name
- NCT06321302
- Testing
- BI 764524, Aflibercept (Eylea®) - US only
- Where
- 90 sites in United States, Germany and 7 more
- Volunteers
- 175 people
- Sponsor
- Boehringer Ingelheim